Does the EU Biotech Act Part I deliver on its promises?  

Yesterday, the European Commission unveiled Part I of the EU Biotech Act, a crucial step to boost Europe’s biotech innovation ecosystem. This first chapter focuses mostly on health, incentivising companies to conduct research and production within Europe, accelerate clinical trials authorisations across countries, and fast-track the development of cutting-edge new therapies using AI, data and regulatory sandboxes. And it proposes amendments to several EU regulations, including the general food law and GMO rules. As we take a closer look at the act during the Christmas holidays, we warmly invite you to share your insights and feedback with us. Your input will help us sharpen our asks and position, enabling us to best support the Dutch government in shaping its national position and ensuring the right steps are taken to strengthen biotech competitiveness in Europe. Our key asks for bold action remain central in our efforts. In the coming days, we’ll assess how Part I measures up to these ambitions and what’s still needed to make Part II (expected in Q3 2026) even bolder and better.